ASSESSING THE ECONOMIC BURDEN OF HEART FAILURE IN KOREA- INCREMENTAL COST APPROACH
Author(s)
Oh S, Cho H, Lee H, Kang H
College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South Korea
OBJECTIVES: Heart failure (HF) is a major cause of morbidity and mortality. With the aging of the Korean population, the prevalence of HF is increasing, thereby increasing the economic burden. This study aimed to assess the economic impact of HF from the restricted societal perspective. METHODS: A prevalence-based, case-controlled, cost-of-illness study was performed to estimate the incremental costs for adult HF patients as compared to those without HF. We defined adult HF patients as those aged 19 years or above who had at least one insurance claim record of outpatient or inpatient services with a primary or a secondary diagnosis of HF (ICD-10 codes of I11.0, I13.0, I13.2, I50.x) from the 2014 Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS) claims data. Costs included medical costs for insurance-covered and non-covered services, transportation costs and time costs of patients and caregivers. RESULTS: The average annual per-capita cost was estimated to be 7.9 million Korean won (KW, 1 US dollar approximately equals to 1,100 KW), 2.3 million KW, and 4.6 million KW for HF patients (n=14,252 patients), non-matched controls (n=1,116,882), and matched controls (n= 57,008), respectively. The incremental cost per case of HF as compared to matched control was 3.3 million KW, which is about 1.7 times higher. For HF patients, medical costs accounted for the largest portion of the total cost (75.13%), followed by caregivers’ cost (12.05%), patient’s productivity loss costs due to morbidity (7.21%), and transportation costs (5.61%). CONCLUSIONS: This study shows that HF brings substantial burden to individual patients. It appears to be necessary to set a priority of allocating health care resources to prevent and to treat HF in our society.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PCV53
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders